BofA analyst Jason Gerberry lowered the firm’s price target on Bristol Myers (BMY) to $67 from $68 and keeps a Buy rating on the shares. The firm adjusted several targets in conjunction with its Q1 preview for its large-cap pharma and small-to-mid cap biopharma coverage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers price target raised to $54 from $45 at Cantor Fitzgerald
- BMY Extends Admilparant Program, Reinforcing Its Bet on Pulmonary Fibrosis
- Trump Trade: U.S. strengthens tariffs on steel, aluminum, copper imports
- White House says imposing tariffs on patented pharmaceutical products
- Trump Trade: President says Iran war will still take weeks